Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

2016 INTA Annual Meeting

Summary

Speakers

Robert D. Carroll

Jessica L. Rothstein

Related Content

Preliminary Injunctive Relief in Trade Secret Cases: When to Move and What to Prove

Patents or Trade Secrets? What Boards and CEOs Should Know in the Age of AI

The Case for Keeping AI Disputes Out of Court

Post-Award Considerations and a Look to the Future (IAM)

Determining When Engineered Biologics May Be Patentable (Law360)

Can AI-Discovered Drugs Be Patented?

AI Drug Discovery Tests the Limits of Patent Law

Watch Out Section 101, the USPTO Has a New Sheriff in Town

Goodwin Advises Embrace on Acquisition by Palo Alto Networks

Naomi Birbach and Alicia Palladino Named 2026 Managing IP Rising Stars

The Legal 500 UK 2027 Highlights the Strength of Goodwin’s UK Platform

Emily Rapalino Named a 2026 BTI Client Service All-Star

Managing IP 2026 Recognizes Goodwin Practices and Lawyers for Excellence in Intellectual Property

Goodwin Advises Royalty Pharma on Acquiring Royalty Interest in AstraZeneca’s cliramitug for Up To $425 Million From Neurimmune

Goodwin Advises Hansoh Pharma on Intellectual Property Aspects for License Collaboration and Strategic Investment With Avere for $120 Million Upfront and Up to $2.18 Billion in Milestone Payments

Goodwin Guides IP for Pharmakon on Up to $200 Million Financing for Kestra Medical Technologies

Intellectual Property

Trademarks